Announcement on the signing of the purchase and sale framework agreement between Sun Company and Shenzhen Guanglin Medical Technology Co., Ltd.
Time:2020-03-27
Classification: Company Announcement
I. Overview of Agreement Signing
1. Shouhang High-tech Energy Technology Co., Ltd. (hereinafter referred to as "the company" or "Shouhang High-tech") Sun Company Shouhang Jieneng (Quanzhou) Medical Technology Co., Ltd. (hereinafter referred to as "Shouhang Medical" or "Party B") and Shenzhen Guanglin Medical Technology Co., Ltd. (hereinafter referred to as "Party A") recently signed the "Purchase and Sale Framework Agreement".
2. The signing of the "Purchase and Sale Framework Agreement" does not constitute a connected transaction, nor does it constitute a major asset reorganization as stipulated in the "Administrative Measures for the Major Asset Reorganization of Listed Companies.
3. The "Purchase and Sale Framework Agreement" is a document of intent for cooperation between the two parties and does not need to be submitted to the board of directors and the general meeting of shareholders for deliberation.
II. Introduction of counterparties
1. Name: Shenzhen Guanglin Medical Technology Co., Ltd.
2. Domicile: Room 201, Building A, No.1 Qianwan 1st Road, Qianhai Shenzhen-Hong Kong Cooperation Zone, Shenzhen City
3. Legal Representative: Wang Danhua
4. Registered capital: 10 million yuan
5. Business scope: general business items are: technical development, technical consultation, technology transfer and technical services of medical devices and equipment and health care devices; sales of cosmetics and skin care products; sales of Class I medical devices and equipment and health care devices; import and export business. (Except for items prohibited by laws, administrative regulations, and decisions of the State Council, restricted items must be licensed before they can be operated), licensed items are: sales of Class II medical devices and Class III medical devices.
6. Shenzhen Guanglin Medical Technology Co.
7. Shenzhen Guanglin Medical Technology Co., Ltd. and the Company did not have similar business in the most recent fiscal year.
III. Main Contents of the Agreement
The first article,From the date of signing of this Agreement, the two parties will cooperate for a period of three years, and Party A will purchase mask supplies from Party B.
Article 2,The masks purchased by Party A from Party B are mainly exported to the United States, Europe and other countries and regions. Party A's main sales channels include Wal-Mart and large overseas pharmaceutical products companies. After Party B's products have obtained relevant qualification certification and passed customer inspection, Party A will issue production and supply tasks to Party B and sign relevant purchase contracts according to the needs of foreign customers.
Article 3,On the premise of giving priority to overseas market development, Party A can sell some masks through its domestic sales channels, and sell some masks to large and medium-sized hospitals and even pharmacies in China. In order to avoid customer or regional conflicts in the process of product sales, Party A shall report to Party B in advance when selling to relevant domestic enterprises. For the earliest reported business, Party B allows Party A to give priority to selling Party B's products to the customer. If Party B judges that Party A's filing is not the earliest filing business due to customer or regional conflicts, Party A has the right to raise objections and claim rights by verifying to the customer, requesting the customer to issue written supporting materials, requesting Party B to provide a basis for judgment, etc.
Article 4,The number of masks purchased by Party A from Party B each year is between 50 million and 80 million. Party B agrees to give priority to the supply of goods to Party A within this quantity range, and Party B undertakes not to supply goods to other parties until Party A's demand is not met. The price is specified in the purchase and supply agreement signed by both parties.
IV. Impact of framework agreements on listed companies
1. The signing of this cooperation agreement will help the company to accelerate the layout of the company's mask business in the domestic and foreign markets with the help of Party A's channels, enhance the competitiveness of the company's mask business in the domestic and foreign markets, and make up for the lack of the company's overseas mask marketing channels.
2. After the signing of this agreement, the two parties will sign purchase and sale agreements of different quantities and requirements in batches for specific procurement needs under the constraints of the relevant framework.
3, the signing of this agreement is in the company to obtain medical device-related qualifications and the United States FDA certification under the premise of the layout of overseas market development, in the current overseas epidemic situation, the company will actively promote the overseas export of related products, enhance the company's health care sector revenue and profits.
FiveRisk Alert
After the signing of this agreement, the two parties still need to sign a specific purchase and sales agreement for related needs, and the sales of related products are still uncertain. The progress of overseas market expansion of the above-mentioned products may be affected by overseas markets, changes in the policy environment, exchange rate fluctuations, market competition and other factors. The signing of this agreement cannot predict the specific impact on the company's performance for the time being. Please the majority of investors to pay attention to investment risk.
6. Documents for Reference
1, "purchase and sale framework agreement".
It is hereby announced.
Shouhang Gaoke Energy Technology Co., Ltd.
Board of Directors
26 March 2020